February 13th 2025
The investigators reported an HR for OS of 0.796 (95% CI, 0.661-0.958; 2-sided P = .0155) for talazoparib/enzalutamide vs enzalutamide/placebo.
February 10th 2025
MPS2 test validated for detection of high-grade prostate cancer in non-DRE urine
January 30th 2025“MPS2 could potentially improve the health of our patients by avoiding overdiagnosis and overtreatment and allowing us to focus on those who are most likely to have aggressive cancers," says Ganesh S. Palapattu, MD, FACS.
Tobias Nordström, MD, on the evolving landscape of prostate cancer screening
January 9th 2025“Another aspect is how to make this more and more complex diagnostic chain for prostate cancer work in practice, because we now have so [many] more tools than we had a decade ago,” says Tobias Nordström, MD, PhD.
Investigators identify potential dual targets in prostate cancer
December 20th 2024“Our findings highlight the coordinated interplay between GCN2 and p53 regulation during nutrient stress and provide insight into how they could be targeted in developing new therapeutic strategies for [prostate cancer]," write the authors.
Adding CAN-2409 to radiation improves DFS in localized prostate cancer
December 13th 2024“If approved, this approach has the potential to transform the treatment paradigm in prostate cancer, offering patients with localized disease an effective treatment option that may reduce the risk of disease recurrence," says Glen Gejerman, MD, MBA.